These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17215031)

  • 1. A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.
    Case AS; Rocconi RP; Partridge EE; Straughn JM
    Gynecol Oncol; 2007 Apr; 105(1):223-7. PubMed ID: 17215031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.
    Rocconi RP; Case AS; Straughn JM; Estes JM; Partridge EE
    Cancer; 2006 Aug; 107(3):536-43. PubMed ID: 16804928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
    Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
    Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
    Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
    Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
    Wysham WZ; Schaffer EM; Coles T; Roque DR; Wheeler SB; Kim KH
    Gynecol Oncol; 2017 May; 145(2):340-345. PubMed ID: 28291545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.
    Plamadeala V; Kelley JL; Chan JK; Krivak TC; Gabrin MJ; Brower SL; Powell MA; Rutherford TJ; Coleman RL
    Gynecol Oncol; 2015 Jan; 136(1):94-8. PubMed ID: 25462203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
    Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
    Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
    Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
    J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is FDA-Approved Bevacizumab Cost-Effective When Included in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer?
    Chappell NP; Miller CR; Fielden AD; Barnett JC
    J Oncol Pract; 2016 Jul; 12(7):e775-83. PubMed ID: 27246689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.
    Dalton HJ; Yu X; Hu L; Kapp DS; Benjamin I; Monk BJ; Chan JK
    Gynecol Oncol; 2012 Feb; 124(2):199-204. PubMed ID: 22055763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy.
    Wallbillich JJ; Forde B; Havrilesky LJ; Cohn DE
    Gynecol Oncol; 2016 Jul; 142(1):144-149. PubMed ID: 27106017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Havrilesky LJ; Secord AA; Kulasingam S; Myers E
    Gynecol Oncol; 2007 Nov; 107(2):211-8. PubMed ID: 17870150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
    Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Huh WK; Straughn JM
    Gynecol Oncol; 2009 Aug; 114(2):242-5. PubMed ID: 19447480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy.
    Chiyoda T; Tsuda H; Nomura H; Kataoka F; Tominaga E; Suzuki A; Susumu N; Aoki D
    Eur J Gynaecol Oncol; 2010; 31(4):364-8. PubMed ID: 20882873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
    Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
    J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
    Lairson DR; Parikh RC; Cormier JN; Du XL
    Value Health; 2014; 17(1):34-42. PubMed ID: 24438715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?
    Tanner EJ; Chi DS; Eisenhauer EL; Diaz-Montes TP; Santillan A; Bristow RE
    Gynecol Oncol; 2010 May; 117(2):336-40. PubMed ID: 20153027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    Wolford JE; Bai J; Moore KN; Kristeleit R; Monk BJ; Tewari KS
    Gynecol Oncol; 2020 May; 157(2):500-507. PubMed ID: 32173049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.